{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:59:27Z","timestamp":1760853567073,"version":"3.38.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,11,16]],"date-time":"2011-11-16T00:00:00Z","timestamp":1321401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1007\/s00213-011-2567-y","type":"journal-article","created":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T10:56:13Z","timestamp":1321354573000},"page":"249-259","source":"Crossref","is-referenced-by-count":31,"title":["Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test"],"prefix":"10.1007","volume":"221","author":[{"given":"Barbara","family":"Langen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Dost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Egerland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Stange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Hoefgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,11,16]]},"reference":[{"issue":"Suppl 2","key":"2567_CR1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-2007-979354","volume":"31","author":"WM Abi-Saab","year":"1998","unstructured":"Abi-Saab WM, D\u2019Souza DC, Moghaddam B, Krystal JH (1998) The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31(Suppl 2):104\u2013109. doi: 10.1055\/s-2007-979354-x","journal-title":"Pharmacopsychiatry"},{"key":"2567_CR2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1176\/ajp.135.9.1081","volume":"135","author":"RM Allen","year":"1978","unstructured":"Allen RM, Young SJ (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135:1081\u20131084","journal-title":"Am J Psychiatry"},{"key":"2567_CR3","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/j.1471-4159.2007.05047.x","volume":"104","author":"NC Anastasio","year":"2008","unstructured":"Anastasio NC, Johnson KM (2008) Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat. J Neurochem 104:1210\u20131218. doi: 10.1111\/j.1471-4159.2007.05047","journal-title":"J Neurochem"},{"key":"2567_CR4","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0022-3565(24)35047-5","volume":"290","author":"P Andin\u00e9","year":"1999","unstructured":"Andin\u00e9 P, Widermark N, Axelsson R, Nyberg G, Olofsson U, Martensson E, Sandberg M (1999) Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther 290:1393\u20131408","journal-title":"J Pharmacol Exp Ther"},{"key":"2567_CR5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0022-3565(24)38228-X","volume":"289","author":"VL Arvanov","year":"1999","unstructured":"Arvanov VL, Wang RY (1999) Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine. J Pharmacol Exp Ther 289:1000\u20131006","journal-title":"J Pharmacol Exp Ther"},{"key":"2567_CR6","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.physbeh.2008.11.002","volume":"96","author":"MC Audet","year":"2009","unstructured":"Audet MC, Goulet S, Dor\u00e9 FY (2009) Impaired social motivation and increased aggression in rats subchronically exposed to phencyclidine. Physiol Behav 96:394\u2013398. doi: 10.1016\/j.physbeh.2008.11.002","journal-title":"Physiol Behav"},{"key":"2567_CR7","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neubiorev.2010.01.012","volume":"34","author":"JH Barnett","year":"2010","unstructured":"Barnett JH, Robbins TW, Leeson VC, Sahakian BJ, Joyce EM, Blackwell AD (2010) Assessing cognitive function in clinical trials of schizophrenia. Neurosci Biobehav Rev 34:1161\u20131177. doi: 10.1016\/j.neubiorev.2010.01.012","journal-title":"Neurosci Biobehav Rev"},{"key":"2567_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/10673229309017065","volume":"1","author":"FM Benes","year":"1993","unstructured":"Benes FM (1993) The relationship between structural brain imaging and histopathologic findings in schizophrenia research. Harv Rev Psychiatry 1:100\u2013109","journal-title":"Harv Rev Psychiatry"},{"key":"2567_CR9","first-page":"166","volume":"2","author":"A bi-Dargham","year":"2003","unstructured":"bi-Dargham A (2003) Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us? World Psychiatry 2:166\u2013171","journal-title":"World Psychiatry"},{"key":"2567_CR10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3109\/10401239709147802","volume":"9","author":"JS Brar","year":"1997","unstructured":"Brar JS, Chengappa KN, Parepally H, Sandman AR, Kreinbrook SB, Sheth SA, Ganguli R (1997) The effect of clozapine on negative symptoms in patients with schizophrenia with minimla positive symptoms. Ann Clin Psychiatry 9:227\u2013234","journal-title":"Ann Clin Psychiatry"},{"key":"2567_CR11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/0929867024606939","volume":"9","author":"B Capuano","year":"2002","unstructured":"Capuano B, Crosby IT, Lloyd EJ (2002) Schizophrenia: genesis, receptorology and current therapeutics. Curr Med Chem 9:521\u2013548","journal-title":"Curr Med Chem"},{"key":"2567_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-9964(96)00060-6","volume":"22","author":"AG Cardno","year":"1996","unstructured":"Cardno AG, Jones LA, Murphy KC, Asherson P, Scott LC, Williams J, Owen MJ, McGuffin P (1996) Factor analysis of schizophrenic symptoms using the OPCRIT checklist. Schizophr Res 22:233\u2013239","journal-title":"Schizophr Res"},{"key":"2567_CR13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.bbr.2010.08.001","volume":"216","author":"M Chatterjee","year":"2011","unstructured":"Chatterjee M, Ganguly S, Srivastava M, Palit G (2011) Effect of \u201cchronic\u201d versus \u201cacute\u201d ketamine administration and its withdrawal effect on behavioural alterations in mice: implications for experimental psychosis. Behav Brain Res 216:247\u2013254. doi: 10.1016\/j.bbr.2010.08.001","journal-title":"Behav Brain Res"},{"key":"2567_CR14","doi-asserted-by":"crossref","first-page":"S211","DOI":"10.1016\/S0893-133X(99)00128-1","volume":"21","author":"R Corbett","year":"1999","unstructured":"Corbett R, Zhou L, Sorensen SM, Mondadori C (1999) Animal models of negative symptoms: M100907 antagonizes PCP-induced immobility in a forced swim test in mice. Neuropsychopharm 21:S211\u2013S218","journal-title":"Neuropsychopharm"},{"key":"2567_CR15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0165-6147(02)02017-5","volume":"23","author":"JF Cryan","year":"2002","unstructured":"Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23:238\u2013245. doi: 10.1016\/SO165-6147(02)02017-5","journal-title":"Trends Pharmacol Sci"},{"key":"2567_CR16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3109\/00952997809007016","volume":"5","author":"GG Angelis De","year":"1978","unstructured":"De Angelis GG, Goldstein E (1978) Treatment of adolescent phencyclidine (PCP) abusers. Am J Drug Alcohol Abuse 5:399\u2013414","journal-title":"Am J Drug Alcohol Abuse"},{"key":"2567_CR17","first-page":"691","volume":"8","author":"L Ereshefsky","year":"1989","unstructured":"Ereshefsky L, Watanabe MD, Tran-Johnson TK (1989) Clozapine: an atypical antipsychotic agent. Clin Pharm 8:691\u2013709","journal-title":"Clin Pharm"},{"key":"2567_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02791072.1979.10471408","volume":"11","author":"RE Garey","year":"1979","unstructured":"Garey RE (1979) PCP (phencyclidine): an update. J Psychedelic Drugs 11:265\u2013275","journal-title":"J Psychedelic Drugs"},{"key":"2567_CR19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00213-009-1530-7","volume":"205","author":"G Gilmour","year":"2009","unstructured":"Gilmour G, Pioli EY, Dix SL, Smith JW, Conway MW, Jones WT, Loomis S, Mason R, Shahabi S, Tricklebank MD (2009) Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for \"NMDA antagonist modelling\" of schizophrenia. Psychopharmacology 205:203\u2013216. doi: 10.1007\/s00213-009-1530-7","journal-title":"Psychopharmacology"},{"key":"2567_CR20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","volume":"331","author":"SM Grauer","year":"2009","unstructured":"Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ (2009) Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther 331:574\u2013590. doi: 10.1124\/jpet.109.155994","journal-title":"J Pharmacol Exp Ther"},{"key":"2567_CR21","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1021\/jm1002793","volume":"53","author":"N Hoefgen","year":"2010","unstructured":"Hoefgen N, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Tremmel P, Pangalos MN, Marquis KL, Hage T, Harrison BL, Malamas MS, Brandon NJ, Kronbach T (2010) Discovery of imidazo[1,5a]pyrido[3,2e]pyrazines as a new class of phosphodiesterase 10A inhibitors. J Med Chem 53:4399\u20134411. doi: 10.1021\/jm1002793","journal-title":"J Med Chem"},{"key":"2567_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201\u2013225","journal-title":"Neuropsychopharmacology"},{"key":"2567_CR23","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789\u2013796","journal-title":"Arch Gen Psychiatry"},{"key":"2567_CR24","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1124\/jpet.105.084681","volume":"314","author":"B Langen","year":"2005","unstructured":"Langen B, Egerland U, Bernoester K, Dost R, Unverferth K, Rundfeldt C (2005) Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor. J Pharmacol Exp Ther 314:717\u2013724. doi: 10.1124\/jpet.105.084681","journal-title":"J Pharmacol Exp Ther"},{"key":"2567_CR25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijdevneu.2010.07.234","volume":"29","author":"F Liu","year":"2011","unstructured":"Liu F, Zou X, Sadovova N, Zhang X, Shi L, Guo L, Qian F, Wen Z, Patterson TA, Hanig JP, Paule MG, Wjr S, Wang C (2011) Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia. Int Dev Neurosci 29:351\u2013358. doi: 10.1016\/j.ijdevneu.2010.07.234","journal-title":"Int Dev Neurosci"},{"key":"2567_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0010-440X(94)90164-3","volume":"35","author":"DD Miller","year":"1994","unstructured":"Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994) Clozapine\u2019s effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 35:8\u201315","journal-title":"Compr Psychiatry"},{"key":"2567_CR27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neuint.2007.06.019","volume":"51","author":"A Mouri","year":"2007","unstructured":"Mouri A, Noda Y, Enomoto T, Nabeshima T (2007) Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 51:173\u2013184. doi: 10.1016\/j.neuint.2007.06.019","journal-title":"Neurochem Int"},{"key":"2567_CR28","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0893-133X(98)00067-0","volume":"20","author":"JW Newcomer","year":"1999","unstructured":"Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106\u2013118","journal-title":"Neuropsychopharmacology"},{"key":"2567_CR29","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1111\/j.1476-5381.1995.tb15106.x","volume":"116","author":"Y Noda","year":"1995","unstructured":"Noda Y, Yamada K, Furukawa H, Nabeshima T (1995) Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Brit J Pharmacol 116:2531\u20132537","journal-title":"Brit J Pharmacol"},{"key":"2567_CR30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0014-2999(97)00067-8","volume":"324","author":"Y Noda","year":"1997","unstructured":"Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997) Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324:135\u2013140","journal-title":"Eur J Pharmacol"},{"key":"2567_CR31","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0893-133X(00)00138-X","volume":"23","author":"Y Noda","year":"2000","unstructured":"Noda Y, Kamei H, Mamiya T, Furukawa H, Nabeshima T (2000) Repeated phencyclidine treatment induces negative symptom-like behaviour in forced swimming test in mice: imbalance of prefrontal serotonergic and dopaminergic functions. Neuropsychopharmacology 23:375\u2013387. doi: 10.1038\/sj.npp.1395546","journal-title":"Neuropsychopharmacology"},{"key":"2567_CR32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/archpsyc.1992.01820050009001","volume":"49","author":"D Pickar","year":"1992","unstructured":"Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992) Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 49:345\u2013353","journal-title":"Arch Gen Psychiatry"},{"key":"2567_CR33","first-page":"327","volume":"229","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229:327\u2013336","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2567_CR34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00001756-200101220-00010","volume":"12","author":"H Qiao","year":"2001","unstructured":"Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H, Kayukawa Y, Ohta T, Nabeshima T (2001) Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12:11\u201315","journal-title":"Neuroreport"},{"key":"2567_CR35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1600-0447.1994.tb01615.x","volume":"90","author":"ER Rey","year":"1994","unstructured":"Rey ER, Bailer J, Br\u00e4uer W, H\u00e4ndel M, Laubenstein D, Stein A (1994) Stability trends and longitudinal correlations of negative and positive syndromes within a three-year follow-up of initially hospitalized schizophrenics. Acta Psychitr Scand 90:405\u2013412","journal-title":"Acta Psychitr Scand"},{"key":"2567_CR36","first-page":"3","volume":"7","author":"F Sams-Dodd","year":"1996","unstructured":"Sams-Dodd F (1996) Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7:3\u201323","journal-title":"Behav Pharmacol"},{"key":"2567_CR37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0893-133X(97)00200-5","volume":"19","author":"F Sams-Dodd","year":"1998","unstructured":"Sams-Dodd F (1998) Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 19:18\u201325","journal-title":"Neuropsychopharmacology"},{"key":"2567_CR38","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.107.132910","volume":"325","author":"CJ Schmidt","year":"2008","unstructured":"Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD, Williams RD, Verhoest PR, Menniti FS (2008) Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 325:681\u2013690. doi: 10.1124\/jpet.107.132910","journal-title":"J Pharmacol Exp Ther"},{"key":"2567_CR39","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbr.2009.02.007","volume":"204","author":"A Seillier","year":"2009","unstructured":"Seillier A, Giuffrida A (2009) Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 204:410\u2013415. doi: 10.1016\/j.bbr.2009.02.007","journal-title":"Behav Brain Res"},{"key":"2567_CR40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","volume":"51","author":"JA Siuciak","year":"2006","unstructured":"Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ (2006) Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function. Neuropharmacology 51:374\u2013385. doi: 10.1016\/j.neuropharm.2006.01.012","journal-title":"Neuropharmacology"},{"key":"2567_CR41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-2999(97)00026-5","volume":"323","author":"HP Smith","year":"1997","unstructured":"Smith HP, Nichols DE, Mailman RB, Lawler CP (1997) Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol 323:27\u201336","journal-title":"Eur J Pharmacol"},{"key":"2567_CR42","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2009.06004.x","volume":"109","author":"F Sotty","year":"2009","unstructured":"Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766\u2013775. doi: 10.1111\/j.1471-1459.2009.06004.x","journal-title":"J Neurochem"},{"key":"2567_CR43","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/sj.npp.1300732","volume":"30","author":"H Tsukada","year":"2005","unstructured":"Tsukada H, Nishiyama S, Fukumoto D, Sato K, Kakiuchi T, Domino EF (2005) Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 30:1861\u20131869. doi: 10.1038\/sj.npp.1300732","journal-title":"Neuropsychopharmacology"},{"key":"2567_CR44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","volume":"122","author":"JW Young","year":"2009","unstructured":"Young JW, Powell S, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150\u2013202. doi: 10.1016\/j.pharmthera.2009.02.004","journal-title":"Pharmacol Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2567-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T02:47:35Z","timestamp":1741920455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,16]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["2567"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2567-y","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"type":"print","value":"0033-3158"},{"type":"electronic","value":"1432-2072"}],"subject":[],"published":{"date-parts":[[2011,11,16]]}}}